| Literature DB >> 33105674 |
Raymond K Hau1, Siennah R Miller1, Stephen H Wright2, Nathan J Cherrington1.
Abstract
The blood-testis barrier (BTB) formed by adjacent Sertoli cells (SCs) limits the entry of many chemicals into seminiferous tubules. Differences in rodent and human substrate-transporter selectivity or kinetics can misrepresent conclusions drawn using rodent in vitro models. Therefore, human in vitro models are preferable when studying transporter dynamics at the BTB. This study describes a hTERT-immortalized human SC line (hT-SerC) with significantly increased replication capacity and minor phenotypic alterations compared to primary human SCs. Notably, hT-SerCs retained similar morphology and minimal changes to mRNA expression of several common SC genes, including AR and FSHR. The mRNA expression of most xenobiotic transporters was within the 2-fold difference threshold in RT-qPCR analysis with some exceptions (OAT3, OCT3, OCTN1, OATP3A1, OATP4A1, ENT1, and ENT2). Functional analysis of the equilibrative nucleoside transporters (ENTs) revealed that primary human SCs and hT-SerCs predominantly express ENT1 with minimal ENT2 expression at the plasma membrane. ENT1-mediated uptake of [3H] uridine was linear over 10 min and inhibited by NBMPR with an IC50 value of 1.35 ± 0.37 nM. These results demonstrate that hT-SerCs can functionally model elements of transport across the human BTB, potentially leading to identification of other transport pathways for xenobiotics, and will guide drug discovery efforts in developing effective BTB-permeable compounds.Entities:
Keywords: antiviral; blood–testis barrier; cell immortalization; drug disposition; male contraceptive; nucleoside transport; sertoli cell; testes; uridine; xenobiotic transporter
Year: 2020 PMID: 33105674 PMCID: PMC7690448 DOI: 10.3390/pharmaceutics12111005
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
List of forward and reverse RT-qPCR primers used in this study.
| Gene Name | Forward Primer | Reverse Primer |
|---|---|---|
|
| 5′-CGACCACTTTGTCAAGCTCA-3′ | 5′-CCCTGTTGCTGTAGCCAAAT-3′ |
|
| 5′-CGGTGTGCACCAACATTAC-3′ | 5′-GGGTTCTTCCAAACTTGCTG-3′ |
|
| 5′-CCATAAGCCACTTGGATGCT-3′ | 5′-TGTCATGTCTGAGGCACTCC-3′ |
|
| 5′-AAATGGAGCTTGCATTCTGG-3′ | 5′-TCCTTCCCAGATTCTCCTGA-‘3 |
|
| 5′-TCTTCATGGTTCTGCCCTTC-3′ | 5′-GCTGGGGTTTGTCACTGTTT-3′ |
|
| 5′-AGACCTTTGGGCTGCCTTAT-3′ | 5′-TAGCCTCCCTCACTCCAAGA-3′ |
|
| 5′-ACTGGCTGACCACCTCACT-3′ | 5′-GTTCAGTGGGCACACAACAG-3′ |
|
| 5′-TTCACGGTATTGCAGTGGTAA-3′ | 5′-GTTTCTGATTGCTGCCCATT-3′ |
|
| 5′-GCTGCAAATGGAAGCTTTTC-3′ | 5′-TTCTGGGCACCAAATGTTTT-3′ |
|
| 5′-CCATGTGAAGAGGGAGAAGC-3′ | 5′-AAGACAGTCCCCCTTGAGGT-3′ |
|
| 5′-CCATCCTTTCTCCCTCGTTT-3′ | 5′-TTCCCTCCAATGTTTCATTCA-3′ |
|
| 5′-TGAACGCACATGACATAGCA-3′ | 5′-ACGTGGCACTTGGACATCTA-3′ |
|
| 5′-ATGCCTAGCTACCCCATCT-3′ | 5′-AATGCCAATCCTGCATTCTC-3′ |
|
| 5′-CTCCCCTCCTTAACCTCTGG-3′ | 5′-AGAGGTTTCCTTCCCCTCAA-3′ |
|
| 5′-AAGCCTGCACTTTCCGTAGA-3′ | 5′-AAGCCTGCACTTTCCGTAGA-3′ |
|
| 5′-TACCTCCTTGCACAAATGGA-3′ | 5′-CCTGGACCATCCCCTATTTT-3′ |
|
| 5′-CTCGTTAGAGCCCAAAGTGG-3′ | 5′-ACAAAAGGATCCCCCAAAAC-3′ |
|
| 5′-CCGTATCAGGTTTGCCAGTT-3′ | 5′-TGGAGGTGATCCAGGAAAAG-3′ |
|
| 5′-GGCACTGCTGATTGAAGACA-3′ | 5′-TGTCACCTGCACCTTCTCTG-3′ |
|
| 5′-TCCTGATGATGGTGGCTGTA-3′ | 5′-ATGCAATTTCAGGGAGGTGA-3′ |
|
| 5′-AGTTCTGTTTGTTACCCACCAGTT-3′ | 5′-ACCCTTGTCTTGTGACTTCTTCTG-3′ |
|
| 5′-GCTCTATCCTCAGGAACTCGAAGAC-3′ | 5′-GCTTTCTCTGCATTCATAGCATTCT |
|
| 5′-CTACTCTCCTTCGCCACATTTTC-3′ | 5′-TGGCTCAGAGAGGCCTTCTC-3′ |
|
| 5′-CTCCTCAGGGATTTTCACCA-3′ | 5′-AGGACCAGGAACTGCTCTGA-3′ |
|
| 5′-CCAAGACTGACACCCTGGTT-3′ | 5′-GACGTGATCGCAGRRGAGA-3′ |
|
| 5′-AAAGGGCACCCTGGATTACT-3′ | 5′-AATGCAAGTGGGCTCCTATG-3′ |
|
| 5′-GCCAAAGCCAAAATATCAGC-3′ | 5′-TTCCAATGTGTTCGGCATTA-3′ |
|
| 5′-CCCTGACATTCTGTCACAACA-3′ | 5′-GGGACAGGTATGTGAAAAGCA-3′ |
|
| 5′-ATGCTGTTTCCCACCTCTTTG-3′ | 5′-CCGAGGCACGTTGTTTACTT-3′ |
|
| 5′-TGGGGCATATTTTTACCAATG-3′ | 5′-GAACTCGCCCATAGACACAAC-3′ |
|
| 5′-CAGCAACAAGAGCACCAGAA-3′ | 5′-TGGGTCACCATTTCCTCTTC-3′ |
|
| 5′-CCCAAGGGACAAAAAGAACA-3′ | 5′-ATGAGACCAGTGGGTTGGAG-3′ |
|
| 5′-TCCCAGAGGATCCCTCTACA-3′ | 5′-TGCCTGGCTAGGATCAGTCT-3′ |
|
| 5′-TGGAGGCATGGTGAAATACA-3′ | 5′-GTCACCCACTTCCGTGATCT-3′ |
|
| 5′-GATCCTGCCAAATTCTTCCA-3′ | 5′-TAGCCCACAGTTCCCCTATG-3′ |
|
| 5′-ATGGTTGCTGAACCCAAAAC-3′ | 5′-CCCAGATCGTTAAACCCAGA-3′ |
|
| 5′-ACCCCATTTGGTGAAGTGAA-3′ | 5′-GGTTGGTTTGTAAAGCAAGGAC-3′ |
|
| 5′-ATTTGCCCTTCAGAATGCAC-3′ | 5′-GCAGACAATTGCCAGAGTGA-3′ |
|
| 5′-AGGTCCTGCCCATCATTGTC-3′ | 5′-CAAGTAGGGCCGGATCAGTA-3′ |
|
| 5′-AATGGGTGTTTGCAGGAGTC-3′ | 5′-GAAGACCTAGGCCCGAAAAC-3′ |
|
| 5′-GCTGGGTCTGACCGTTGTAT-3′ | 5′-CTGTACAGGGTGCATGATGG-3′ |
|
| 5′-AGCCTGCATGTGTGTACTGC-3′ | 5′-ACCACGGACCAGTCACTTTC-3′ |
|
| 5′-GCATCAAGGGCAGATGATTT-3′ | 5′-GGCTGGGAAGTCAAGAGATG-3′ |
|
| 5′-GCTGGGGCAGATAGTGAAAC-3′ | 5′-GGACCAGGAACTCCTCAAAA-3′ |
|
| 5′-GAAAAGGTTGTTTAAAGGAATCTGG-3′ | 5′-CGAAATCATCAATGTAAGAAAGCC-3′ |
|
| 5′-ACTCCCATTCAGCCTTTGGG-3′ | 5′-CAGAAAGGCACAGCTGCAAG-3′ |
|
| 5′-TTCCAAAGCCACCTCATTTC-3′ | 5′-GGTTAGTTGCAGGGCATCAT-3′ |
|
| 5′-GGCTTTGAGACTTTCCCACA-3′ | 5′-CTGGGAAACAAGAGGGATGA-3′ |
|
| 5′-CAGGCCATGCTCTCCGAAA-3′ | 5′-CTGCTGCTCCAGGTACTTCC-3′ |
|
| 5′-CTGCCAGCCAGAACACTACA-3′ | 5′-AGAAGGAGGGGCTTTCTCTG-3′ |
|
| 5′-TCATGCTCCCCTACGGTACAG-3′ | 5′-GCTCACCTTTGTTTGGAGTGTTAG-3′ |
|
| 5′-GGAGCCAGGATGAAGTCTCAA-3′ | 5′-GAACCTTATCAAGGCCTCTGGAAG-3′ |
Figure 1(A) Expression vector for pBABE-puro-hTERT [34] used to transfect Phoenix-AMPHO packaging cells for subsequent transduction into primary human SCs. Phase contrast microscopy images at 10× magnification of (B) primary human SCs at passage 4 and (C) immortalized hT-SerCs at passage 21. White arrows indicate tripartite nucleoli [41] within the nucleus of each cell. (D) Relative mRNA expression of human TERT assessed by RT-qPCR using the 2−ΔΔCt method. Ct values were normalized to GAPDH as the reference gene. (E) Representative Western blot of three independent experiments for the expression of human TERT in primary human SCs at passages 4 and 6 (lanes 1–3) and post-passage 20 hT-SerCs (lanes 4–6). The molecular weight ladder is denoted as L. Beta-actin served as the loading control.
Figure 2Transepithelial electrical resistance of primary human SCs at passages 4–6 and post-passage 20 hT-SerCs plated on 24-well Transwell inserts (0.4 μm pore size, 0.33 cm2 surface area) coated with 100 μL of 6.6 μg/mL (2 μg/cm2) human fibronectin. Resistance values were measured every two days for eight days and net resistance values for each insert were calculated by subtracting from cell-free coated inserts. TEER was calculated by multiplying the normalized resistance measurements with the surface area of the insert. Data are represented as the mean ± S.D. of three independent experiments.
Figure 3(A) Relative mRNA expression of various human SC marker genes assessed by RT-qPCR using the 2−ΔΔCt method. Ct values were normalized to GAPDH as the reference gene. (B) Representative Western blot of three independent experiments for the expression of human FSHR in primary human SCs at passages 4–6 (lanes 1–3) and post-passage 20 hT-SerCs (lanes 4–6). (C) Representative Western blot of three independent experiments for the expression of human AR in primary human SCs at passages 4–6 (lanes 1–3) and post-passage 20 hT-SerCs (lanes 4–6). The molecular weight ladder is denoted as L. Beta-actin served as the loading control.
Figure 4(A) Relative mRNA expression of various human xenobiotic efflux transporter genes assessed by RT-qPCR. (B) Relative mRNA expression of human anion and cation transporter genes in the SLC22A family. (C) Relative mRNA expression of human organic anion transporting polypeptide transporter genes in the SLC21 family. OATP1B1 expression was not detected in either cell type and denoted as N.D. (D) Relative mRNA expression of human concentrative and equilibrative nucleoside transporters. All fold-change values were calculated using the 2−ΔΔCt method. Ct values were normalized to GAPDH as the reference gene.
Figure 5(A) Total [3H] uridine accumulation into primary human SCs at passages 4–7 and post-passage 20 hT-SerCs after 10 min of uptake. Approximately 85–90% of uptake is blocked by 5 mM unlabeled uridine, 100 nM NBMPR, and 100 μM NBMPR. Data are represented as the mean ± S.D. of five independent experiments. (B) Time-course experiment of [3H] uridine uptake measured every minute for 10 min. [3H] Uridine uptake is effectively linear over 10 min and approximately 85–90% of uptake is blocked by unlabeled uridine or NBMPR. The best-fit line represents a one-phase association. Data are represented as the mean ± S.E.M. of three independent experiments. (C) Inhibition of [3H] uridine uptake by serially increasing concentrations of NBMPR from 0 to 10 nM. Transport was terminated after 10 min. The best-fit line was fitted using the monophasic inhibition model described by Equation (1). Data are represented as the mean ± S.E.M. of three independent experiments.